{"id":"sibutramine-microcrystalline-cellulose","safety":{"commonSideEffects":[{"rate":"17-24%","effect":"Dry mouth"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"30%","effect":"Headache"},{"rate":"12-18%","effect":"Constipation"},{"rate":"5-10%","effect":"Increased heart rate"},{"rate":"3-5%","effect":"Increased blood pressure"},{"rate":"5-7%","effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL4297557","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sibutramine is a sympathomimetic amine that acts as a norepinephrine-serotonin-dopamine reuptake inhibitor. By blocking the reuptake of these neurotransmitters at presynaptic terminals, it increases their synaptic concentration, leading to enhanced satiety signals and decreased food intake. Microcrystalline cellulose is an inert pharmaceutical excipient used as a bulking agent and filler in the formulation.","oneSentence":"Sibutramine inhibits the reuptake of norepinephrine, serotonin, and dopamine in the central nervous system, increasing satiety and reducing appetite.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:37.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities"}]},"trialDetails":[{"nctId":"NCT05821543","phase":"PHASE4","title":"Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-07-03","conditions":"Obesity","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reduxin®"],"phase":"marketed","status":"active","brandName":"sibutramine+ microcrystalline cellulose","genericName":"sibutramine+ microcrystalline cellulose","companyName":"Promomed, LLC","companyId":"promomed-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sibutramine inhibits the reuptake of norepinephrine, serotonin, and dopamine in the central nervous system, increasing satiety and reducing appetite. Used for Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}